Skip to main content
. 2016 Sep 14;9:5671–5678. doi: 10.2147/OTT.S108171

Table 1.

Smoothened inhibitors currently in development

Drug Manufacturer Trials
BMS-833923 Bristol–Myers Squibb CML (NCT01218477)
Glasdegib (PF-04449913) Pfizer MDS (NCT01842646)
LEQ506 Novartis Solid tumors, medulloblastoma, and aBCC (NCT01106508)
LDE255 Novartis MDS (NCT02323139)

Abbreviations: CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; aBCC, advanced basal cell carcinoma.